Petros Pharmaceuticals Inc. (NASDAQ: PRPI) Conducting Stendra Pilot Study Seeking OTC status from the FDA

July 28, 2021

Petros Pharmaceuticals Inc. (NASDAQ: PRPI)  has completed a small pilot label comprehension study which is the first step in the process of obtaining an over-the-counter starter for its erectile dysfunction drug, Stendra, from the US FDA.   Stendra is in the process to receive OTC status Stendra has FDA approval as an oral phosphodiesterase 5 (PDE5) prescription inhibitor for erectile dysfunction treatment.  Chief commercial officer Fady Boctor said there is an…